Warning: The NCBI web site requires JavaScript to function. more...
An HIV/AIDS Prophylactic vaccine is possible.
Zhong Q, Luftig RB.
J Immune Based Ther Vaccines. 2007 Dec 19;5:12.
Related citations
Comparative clonal analysis of human immunodeficiency virus type 1 (HIV-1)-specific CD4+ and CD8+ cytolytic T lymphocytes isolated from seronegative humans immunized with candidate HIV-1 vaccines.
Hammond SA, Bollinger RC, Stanhope PE, Quinn TC, Schwartz D, Clements ML, Siliciano RF.
J Exp Med. 1992 Dec 1;176(6):1531-42.
Final Report on Carcinogens Background Document for Formaldehyde.
National Toxicology Program.
Rep Carcinog Backgr Doc. 2010 Jan;(10-5981):i-512.
Immunogenic profiling in mice of a HIV/AIDS vaccine candidate (MVA-B) expressing four HIV-1 antigens and potentiation by specific gene deletions.
García-Arriaza J, Nájera JL, Gómez CE, Sorzano CO, Esteban M.
PLoS One. 2010 Aug 24;5(8):e12395.
Post-infection immunodeficiency virus control by neutralizing antibodies.
Yamamoto H, Kawada M, Takeda A, Igarashi H, Matano T.
PLoS One. 2007 Jun 20;2(6):e540.
The hunt for the AIDS vaccine.
Essex M.
AIDS Asia. 1995 May-Jun;2(3):10-3.
HIV-1 proteins in infected cells determine the presentation of viral peptides by HLA class I and class II molecules and the nature of the cellular and humoral antiviral immune responses--a review.
Becker Y.
Virus Genes. 1994 Jul;8(3):249-70. Review.
Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group.
Belshe RB, Gorse GJ, Mulligan MJ, Evans TG, Keefer MC, Excler JL, Duliege AM, Tartaglia J, Cox WI, McNamara J, Hwang KL, Bradney A, Montefiori D, Weinhold KJ.
AIDS. 1998 Dec 24;12(18):2407-15.
Neutralizing antibodies against the V3 loop of human immunodeficiency virus type 1 gp120 block the CD4-dependent and -independent binding of virus to cells.
Valenzuela A, Blanco J, Krust B, Franco R, Hovanessian AG.
J Virol. 1997 Nov;71(11):8289-98.
HIV gp120 vaccine - VaxGen: AIDSVAX, AIDSVAX B/B, AIDSVAX B/E, HIV gp120 vaccine - Genentech, HIV gp120 vaccine AIDSVAX - VaxGen, HIV vaccine AIDSVAX - VaxGen.
Adis International Ltd.
Drugs R D. 2003;4(4):249-53.
Multifunctional T-cell characteristics induced by a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine regimen given to healthy adults are dependent on the route and dose of administration.
Bansal A, Jackson B, West K, Wang S, Lu S, Kennedy JS, Goepfert PA.
J Virol. 2008 Jul;82(13):6458-69. Epub 2008 Apr 30.
Brucella abortus conjugated with a gp120 or V3 loop peptide derived from human immunodeficiency virus (HIV) type 1 induces neutralizing anti-HIV antibodies, and the V3-B. abortus conjugate is effective even after CD4+ T-cell depletion.
Golding B, Inman J, Highet P, Blackburn R, Manischewitz J, Blyveis N, Angus RD, Golding H.
J Virol. 1995 Jun;69(6):3299-307.
Impact of cytotoxic-T-lymphocyte memory induction without virus-specific CD4+ T-Cell help on control of a simian immunodeficiency virus challenge in rhesus macaques.
Tsukamoto T, Takeda A, Yamamoto T, Yamamoto H, Kawada M, Matano T.
J Virol. 2009 Sep;83(18):9339-46. Epub 2009 Jul 8.
V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Trials Network.
Montefiori DC, Graham BS, Zhou J, Zhou J, Bucco RA, Schwartz DH, Cavacini LA, Posner MR.
J Clin Invest. 1993 Aug;92(2):840-7.
Potent CD4+ T cell responses elicited by a bicistronic HIV-1 DNA vaccine expressing gp120 and GM-CSF.
Barouch DH, Santra S, Tenner-Racz K, Racz P, Kuroda MJ, Schmitz JE, Jackson SS, Lifton MA, Freed DC, Perry HC, Davies ME, Shiver JW, Letvin NL.
J Immunol. 2002 Jan 15;168(2):562-8.
Brucella abortus conjugated with a peptide derived from the V3 loop of human immunodeficiency virus (HIV) type 1 induces HIV-specific cytotoxic T-cell responses in normal and in CD4+ cell-depleted BALB/c mice.
Lapham C, Golding B, Inman J, Blackburn R, Manischewitz J, Highet P, Golding H.
J Virol. 1996 May;70(5):3084-92.
Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategies.
Garber DA, O'Mara LA, Zhao J, Gangadhara S, An I, Feinberg MB.
PLoS One. 2009;4(5):e5445. Epub 2009 May 6.
Immunization with a soluble CD4-gp120 complex preferentially induces neutralizing anti-human immunodeficiency virus type 1 antibodies directed to conformation-dependent epitopes of gp120.
Kang CY, Hariharan K, Nara PL, Sodroski J, Moore JP.
J Virol. 1994 Sep;68(9):5854-62.
Antigenic properties of the human immunodeficiency virus envelope during cell-cell fusion.
Finnegan CM, Berg W, Lewis GK, DeVico AL.
J Virol. 2001 Nov;75(22):11096-105.
Differential CD4+ versus CD8+ T-cell responses elicited by different poxvirus-based human immunodeficiency virus type 1 vaccine candidates provide comparable efficacies in primates.
Mooij P, Balla-Jhagjhoorsingh SS, Koopman G, Beenhakker N, van Haaften P, Baak I, Nieuwenhuis IG, Kondova I, Wagner R, Wolf H, Gómez CE, Nájera JL, Jiménez V, Esteban M, Heeney JL.
J Virol. 2008 Mar;82(6):2975-88. Epub 2008 Jan 9.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on